Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know

Salim S. Virani; Marlys L. Koschinsky; Lisa Maher; Anurag Mehta; Carl E. Orringer; Raul D. Santos; Michael D. Shapiro; Joseph J. Saseen

doi:10.1016/j.pcad.2022.01.002

Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know

Salim S. Virani, Marlys L. Koschinsky, Lisa Maher, Anurag Mehta, Carl E. Orringer, Raul D. Santos, Michael D. Shapiro, Joseph J. Saseen

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

Abstract

Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the development of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recommendations vary regarding how clinicians should incorporate Lp(a) into patient care. To provide practical answers to key questions pertaining to Lp(a) that clinicians will find useful when assessing and treating patients, a global think tank was convened. Representatives from seven national and international stakeholder organizations answered questions that were focused on: Lp(a) measurement; ethnic, gender, and age considerations; factoring Lp(a) into risk assessment; and current and emerging treatment options for elevated Lp(a). This manuscript summarizes the finding from this global think tank. Areas requiring further investigation were identified, and the need to standardize reporting of Lp(a) levels to ensure harmonization and comparability across laboratories and research studies is emphasized.

Original language	English
Pages (from-to)	32-40
Number of pages	9
Journal	Progress in Cardiovascular Diseases
Volume	73
DOIs	https://doi.org/10.1016/j.pcad.2022.01.002
Publication status	Published - 1 Jul 2022
Externally published	Yes

Keywords

Atherosclerotic cardiovascular disease
Hypercholesterolemia
Lipoprotein(a)
Low-density lipoprotein

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pcad.2022.01.002

Cite this

Virani, S. S., Koschinsky, M. L., Maher, L., Mehta, A., Orringer, C. E., Santos, R. D., Shapiro, M. D., & Saseen, J. J. (2022). Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Progress in Cardiovascular Diseases, 73, 32-40. https://doi.org/10.1016/j.pcad.2022.01.002

@article{f5fe7f61daf240439eccd3ffe033e5da,

title = "Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know",

abstract = "Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the development of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recommendations vary regarding how clinicians should incorporate Lp(a) into patient care. To provide practical answers to key questions pertaining to Lp(a) that clinicians will find useful when assessing and treating patients, a global think tank was convened. Representatives from seven national and international stakeholder organizations answered questions that were focused on: Lp(a) measurement; ethnic, gender, and age considerations; factoring Lp(a) into risk assessment; and current and emerging treatment options for elevated Lp(a). This manuscript summarizes the finding from this global think tank. Areas requiring further investigation were identified, and the need to standardize reporting of Lp(a) levels to ensure harmonization and comparability across laboratories and research studies is emphasized.",

keywords = "Atherosclerotic cardiovascular disease, Hypercholesterolemia, Lipoprotein(a), Low-density lipoprotein",

author = "Virani, {Salim S.} and Koschinsky, {Marlys L.} and Lisa Maher and Anurag Mehta and Orringer, {Carl E.} and Santos, {Raul D.} and Shapiro, {Michael D.} and Saseen, {Joseph J.}",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = jul,

day = "1",

doi = "10.1016/j.pcad.2022.01.002",

language = "English",

volume = "73",

pages = "32--40",

journal = "Progress in Cardiovascular Diseases",

issn = "0033-0620",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Global think tank on the clinical considerations and management of lipoprotein(a)

T2 - The top questions and answers regarding what clinicians need to know

AU - Virani, Salim S.

AU - Koschinsky, Marlys L.

AU - Maher, Lisa

AU - Mehta, Anurag

AU - Orringer, Carl E.

AU - Santos, Raul D.

AU - Shapiro, Michael D.

AU - Saseen, Joseph J.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the development of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recommendations vary regarding how clinicians should incorporate Lp(a) into patient care. To provide practical answers to key questions pertaining to Lp(a) that clinicians will find useful when assessing and treating patients, a global think tank was convened. Representatives from seven national and international stakeholder organizations answered questions that were focused on: Lp(a) measurement; ethnic, gender, and age considerations; factoring Lp(a) into risk assessment; and current and emerging treatment options for elevated Lp(a). This manuscript summarizes the finding from this global think tank. Areas requiring further investigation were identified, and the need to standardize reporting of Lp(a) levels to ensure harmonization and comparability across laboratories and research studies is emphasized.

AB - Evidence from Mendelian randomization studies suggest that lipoprotein(a) (Lp(a)) has a causal role in the development of atherosclerotic cardiovascular disease risk. However, guidelines and consensus statement recommendations vary regarding how clinicians should incorporate Lp(a) into patient care. To provide practical answers to key questions pertaining to Lp(a) that clinicians will find useful when assessing and treating patients, a global think tank was convened. Representatives from seven national and international stakeholder organizations answered questions that were focused on: Lp(a) measurement; ethnic, gender, and age considerations; factoring Lp(a) into risk assessment; and current and emerging treatment options for elevated Lp(a). This manuscript summarizes the finding from this global think tank. Areas requiring further investigation were identified, and the need to standardize reporting of Lp(a) levels to ensure harmonization and comparability across laboratories and research studies is emphasized.

KW - Atherosclerotic cardiovascular disease

KW - Hypercholesterolemia

KW - Lipoprotein(a)

KW - Low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=85123717975&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2022.01.002

DO - 10.1016/j.pcad.2022.01.002

M3 - Review article

C2 - 35063437

AN - SCOPUS:85123717975

SN - 0033-0620

VL - 73

SP - 32

EP - 40

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

ER -

Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this